Rigel Pharmaceuticals Net Worth
Rigel Pharmaceuticals Net Worth Breakdown | RIGL |
Rigel Pharmaceuticals Net Worth Analysis
Rigel Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Rigel Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Rigel Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Rigel Pharmaceuticals' net worth analysis. One common approach is to calculate Rigel Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Rigel Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Rigel Pharmaceuticals' net worth. This approach calculates the present value of Rigel Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Rigel Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Rigel Pharmaceuticals' net worth. This involves comparing Rigel Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Rigel Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Rigel Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Rigel Pharmaceuticals' net worth research are outlined below:
| Rigel Pharmaceuticals is way too risky over 90 days horizon | |
| Rigel Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Rigel Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 116.88 M. Net Loss for the year was (25.09 M) with profit before overhead, payroll, taxes, and interest of 53.72 M. | |
| Rigel Pharmaceuticals currently holds about 81.64 M in cash with (5.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47. | |
| Rigel Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 68.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Raul Rodriguez of 300000 shares of Rigel Pharmaceuticals at 1.87 subject to Rule 16b-3 |
Rigel Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Rigel Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Rigel Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Rigel Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Rigel Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rigel Pharmaceuticals backward and forwards among themselves. Rigel Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Rigel Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-09-30 | 144.3 K | Renaissance Technologies Corp | 2024-09-30 | 141.9 K | Ing Investment Management Llc | 2024-06-30 | 118.9 K | Jane Street Group Llc | 2024-06-30 | 105.9 K | Ubs O'connor Llc | 2024-06-30 | 92.4 K | Kennedy Capital Management Inc | 2024-06-30 | 89.9 K | Squarepoint Ops Llc | 2024-06-30 | 80.9 K | Charles Schwab Investment Management Inc | 2024-09-30 | 77.4 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 75.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.8 M | Armistice Capital, Llc | 2024-06-30 | 1.6 M |
Follow Rigel Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 458.69 M.Market Cap |
|
Project Rigel Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | 0.88 | 0.92 |
When accessing Rigel Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Rigel Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Rigel Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Rigel Pharmaceuticals' management efficiency
Rigel Pharmaceuticals has return on total asset (ROA) of 0.0461 % which means that it generated a profit of $0.0461 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9905) %, meaning that it created substantial loss on money invested by shareholders. Rigel Pharmaceuticals' management efficiency ratios could be used to measure how well Rigel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 0.92 this year, although the value of Return On Tangible Assets will most likely fall to (0.25). At this time, Rigel Pharmaceuticals' Fixed Asset Turnover is quite stable compared to the past year. Asset Turnover is expected to rise to 1.05 this year, although the value of Other Current Assets will most likely fall to about 4.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.65) | (1.56) | |
| Tangible Book Value Per Share | (2.44) | (2.32) | |
| Enterprise Value Over EBITDA | (16.50) | (17.32) | |
| Price Book Value Ratio | (8.81) | (8.37) | |
| Enterprise Value Multiple | (16.50) | (17.32) | |
| Price Fair Value | (8.81) | (8.37) | |
| Enterprise Value | 322.1 M | 306 M |
At Rigel Pharmaceuticals, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 2.9072 | Revenue 157.4 M | Quarterly Revenue Growth 0.966 | Revenue Per Share 8.979 | Return On Equity (6.99) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rigel Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rigel Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rigel Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rigel Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 19th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Rigel Pharmaceuticals Earnings per Share Projection vs Actual
Rigel Pharmaceuticals Corporate Management
| Raymond JD | General VP | Profile | |
| Tarek Sallam | Vice Marketing | Profile | |
| David Santos | Executive Officer | Profile | |
| Julie Patel | Senior Resources | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share 0.27 | Revenue Per Share 8.979 | Quarterly Revenue Growth 0.966 | Return On Assets 0.0461 |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.